Repligen Reports Strong Q2 Earnings and Raises Full-Year Guidance
Repligen Corporation (NASDAQ:RGEN) reported second-quarter revenue of $204 million, reflecting a 12% year-over-year increase on both a reported basis and 13% organic growth. The company's performance was driven by strong demand for proteins (+50%) and analytics products (+over 30%). Adjusted earnings per share rose to $0.54, up 46%, with an expanded adjusted operating margin of 16.7%. Management raised its full-year revenue guidance to a range of 10.5%–13.5% organic growth and increased adjusted EPS expectations to between $2.03 and $2.09. Repligen also announced plans to acquire BioLife in the fourth quarter, which is expected to expand its cell-therapy offerings. The company anticipates at least $20 million in first-year synergies from this acquisition, with adjusted EPS accretion of $0.05 and potential for further gains by year two. CEO Olivier Loeillot noted improved order trends across several product lines, including a sequential pickup in equipment orders.
Tickers: $RGEN
Topics: acquisition adjusted_eps guidance_update revenue_growth